Accueil>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>Tyrphostin AG30

Tyrphostin AG30

Catalog No.GC38125

La tyrphostine AG30 (AG30) est un inhibiteur puissant et sélectif de la tyrosine kinase EGFR. La tyrphostine AG30 (AG30) inhibe sélectivement l'induction de l'auto-renouvellement par c-ErbB et est capable d'inhiber l'activation de STAT5 par c-ErbB dans les érythroblastes primaires.

Products are for research use only. Not for human use. We do not sell to patients.

Tyrphostin AG30 Chemical Structure

Cas No.: 122520-79-0

Taille Prix Stock Qté
10mM (in 1mL DMSO)
58,00 $US
En stock
2mg
52,00 $US
En stock
5mg
81,00 $US
En stock
10mg
102,00 $US
En stock
25mg
225,00 $US
En stock
50mg
398,00 $US
En stock
100mg
663,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tyrphostin AG30 (AG30) is a potent protein tyrosine kinases (PTK) inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts[1][2].

[1]. Volberg T, et al. The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J. 1992 May;11(5):1733-42. [2]. Wessely O, et al. Distinct roles of the receptor tyrosine kinases c-ErbB and c-Kit in regulating the balance between erythroid cell proliferation and differentiation. Cell Growth Differ. 1997 May;8(5):481-93.

Avis

Review for Tyrphostin AG30

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tyrphostin AG30

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.